Estudio microperimétrico en pacientes näive con edema macular diabético tras primera dosis anti-VEGFestudio prospectivo

  1. María Alberto Pestano
  2. R. Abreu González
  3. M. Alonso Plasencia
  4. M. A. Gil Hernández
Revista:
Archivos de la Sociedad Canaria de Oftalmología

ISSN: 0211-2698

Any de publicació: 2021

Número: 32

Pàgines: 113-118

Tipus: Article

DIALNET GOOGLE SCHOLAR

Altres publicacions en: Archivos de la Sociedad Canaria de Oftalmología

Resum

Purpose: To study morphological and functional changes after anti-VEGF treatment in patients with diabetic macular edema (DME). Methods: This prospective study included consecutive naïve patients with DME that started treatment with Ranibizumab or Aflibercept in our center. All patients underwent best corrected visual acuity (BCVA) measurement, microperimetry with strategy 4-2 through fasttesting 13 central points, and OCT-A by using MP-3/RS-3000 advance (Nidek, Gamagori, Japan) before and 1 week after intravitreal treatment. Results: We collected data from a total of 17 eyes from 15 patients. In the sample, 64,7% and 35,3% presented non-proliferative and proliferative diabetic retinopathy respectively. The distribution of intravitreal injections was: 10 patients with ranibizumab and 7 patients with aflibercept. Before and after treatment the results were: mean BCVA pre- and posttreatment: 0.54 ± 0.25 and 0.54 ± 0.29 (p = 0.45); mean central retinal thickness (CRT) pre- and post-treatment: 399 ± 109 μm and 334 ± 69 μm (p = 0.02); mean retinal sensitivity (RS) pre- and post-treatment 21,3 ± 7,4 and 23,6 ± 5,1 (p = 0.05). Conclusions: In the first week of anti-VEGF treatment in naïve patients with EMD, significant functional changes are observed according to the results of our study.

Referències bibliogràfiques

  • Engelgau MM, Geiss LS, Saddine JB, Boyle JP, Benjamin SM, Gregg EW et al. The envolving diabetes burden in the United States. Ann Intern Med 2004; 140(11): 954-950.
  • Tan, G. S., Cheung, N., Simó, R., Cheung, G. C., & Wong, T. Y. (2017). Diabe-tic macular oedema. The lancet. Diabetes & endocrinology, 5(2), 143-155.
  • Pereira, F., Godoy, B. R., Maia, M., & Regatieri, C. V. (2019). Microperimetry and OCT angiography evaluation of patients with ischemic diabetic macular edema treated with monthly intravitreal bevacizumab: a pilot study. International journal of retina and vitreous, 5, 24.
  • Balasubramanian S, Uji A, Lei J, Velaga S, Nittala M, Sadda S. Interdevice comparison of retinal sensitivity assessments in a healthy population: the CenterVue MAIA and the Nidek MP-3 microperimeters. Br J Ophthalmol. 2018; 102(1): 109-113.
  • Vila Franca M, Silva T, Pinto R., Ornelas C, Caldeira Rosa P, Castanheira-Dinis A. Microperimetria no Diagnóstico Precoce da Toxicidade por Hidroxicloroquina Oftalmologia - Vol. 34: 529-536.
  • Al Shafaee M, Shenoy R, Bialasiewicz AA, Ganguly SS, Bhargava K. Macular function in prediabetic and diabetic Omani adults: a microperimetric evaluation. Eur J Ophthalmol. 2011; 21(6): 771-776.
  • Midena E, Bini S. Multimodal retinal imaging of diabetic macular edema: toward new paradigms of pathophysiology. Graefes Arch Clin Exp Ophthalmol. 2016 Sep; 254(9): 1661-8.
  • Wang JW, ,Jie CH, Tao YJ, Meng N, Hu YC,. Macular integrity assesment to de-termine the association between macular microstructure and functional parameters in diabetic macular edema. Int J Ophtalmol 2018; 11(7): 1185- 1191.
  • De Benedetto U, Querques G, Lattanzio R, et al. Macular dysfunction is common in both type 1 and type 2 diabetic patients without macular edema. Retina. 2014; 34(11): 2171-2177.
  • Verma A, Rani PK, Raman R, et al. Is neuronal dysfunction an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabeticretinopathy. Eye (Lond). 2009; 23(9): 1824- 1830.
  • Nittala MG, Gella L, Raman R, Sharma T. Measuring retinal sensitivity with the microperimeter in patients with diabetes. Retina. 2012; 32(7): 1302-1309.
  • Chun DW, Heier JS, Topping TM, Duker JS & Bankert JM (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with center involving clinically significant diabetic macular edema. Ophthalmology 113: 1706-1712.
  • Deissler HL, Deissler H & Lang GE(2011): Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Br J Ophthalmol 95: 1151-1156.
  • Comyn O, Sivaprasad S, Peto T. A randomized trial to asses functional and structural effect of Ranibizumab vs laser in diabetic macular edema (The LUCIDATE Study). Am J Ophthalmol 2014; 157: 960-970.
  • Vujosevic S, Berton M, Bini S, Casciano M, Cavarzeran F, Midena E. Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in centerinvolving diabetic macular edema. Retina. 2016 Jul; 36 (7): 1298-308.
  • Alonso-Plasencia M, Abreu-González R, Gómez-Culebras MA. Structure-Function Correlation Using OCT Angiography And Microperimetry In Diabetic Retinopathy. Clin Ophthalmol. 2019; 13: 2181-2188. Published 2019 Nov 11.
  • Pereira, F., Godoy, B. R., Maia, M., & Regatieri, C. V. (2019). Microperimetry and OCT angiography evaluation of patients with ischemic diabetic macular edema treated with monthly intravitreal bevacizumab: a pilot study. International journal of retina and vitreous, 5, 24.
  • Vujosevic S, Torresin T, Bini S, Convento E, Pilotto E, Parrozzani R, Midena E. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular edema. Acta Ophthalmol. 2017 Aug; 95(5): 464-471.
Fuente de los datos: Dialnet